Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis

被引:31
|
作者
Paulke-Korinek, Maria [1 ,2 ]
Kollaritsch, Herwig [1 ]
Kundi, Michael [3 ]
Zwazl, Ines [1 ]
Seidl-Friedrich, Claudia [1 ]
Jelinek, Tomas [4 ]
机构
[1] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, A-1090 Vienna, Austria
[2] Fed Minist Hlth, Vienna, Austria
[3] Med Univ Vienna, Ctr Publ Hlth, Inst Environm Hlth, A-1090 Vienna, Austria
[4] Berlin Ctr Travel & Trop Med, Berlin, Germany
关键词
Japanese encephalitis vaccine; Long-term protection; Low responder; IMMUNITY; CELLS; TBE;
D O I
10.1016/j.vaccine.2015.05.037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Japanese Encephalitis (JE) virus occurs in wide regions of Asia with over 3 billion people living in areas at risk for JE. An estimated 68,000 clinical cases of JE occur every year, and vaccination is the most effective prophylactic measure. One internationally licensed vaccine containing the inactivated JE virus strain SA(14)-14-2 is lxiaro (R) (Valneva, Austria). According to recommendations, basic immunization consists of vaccinations on day 0, day 28, and a booster dose 12-24 months later. Protection in terms of neutralizing antibody titers has been assessed up to 12 months after the third dose of the vaccine. The current investigation was designed to evaluate antibody decline over time and to predict long-term duration of seroprotection after a booster dose. Method: In a preceding trial, volunteers received basic immunization (day 0, day 28) and one booster dose against JE 15 months later. A follow up blood draw 6 years following their booster dose was carried out in 67 subjects. For antibody testing, a 50% plaque reduction neutralization test (PRNT50-test) was used. PRNT50 values of 10 and above are surrogate levels of protection according to WHO standards. Result: Seventy-six months following the booster dose, 96% of the tested subjects had PRNT50 titers of 10 or higher. Geometric mean titer (GMT) was 148 (95% CI confidence interval: 107-207). Antibody titers were lower in volunteers 50 years of age and older. Vaccination history against other flaviviruses (yellow fever or tick borne encephalitis) did not significantly influence PRNT50 titers. A two-step log-linear decline model predicted protection against JE of approximately 14 years after the booster dose. Conclusion: Six years after a booster dose against JE, long-term protection could be demonstrated. According to our results, further booster doses should be scheduled 10 years following the first booster dose. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3600 / 3604
页数:5
相关论文
共 50 条
  • [1] Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose
    Kadlecek, Vera
    Borja-Tabora, Charissa Fay
    Eder-Lingelbach, Susanne
    Gatchalian, Salvacion
    Kiermayr, Sigrid
    Sablan, Benjamin, Jr.
    Kundi, Michael
    Taucher, Christian
    Dubischar, Katrin L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (09) : E233 - E240
  • [2] Persistence of antibodies after vaccination against tick-borne encephalitis
    Rendi-Wagner, Pamela
    Zent, Olaf
    Jilg, Wolfgang
    Plentz, Annelie
    Beran, Jiri
    Kollaritsch, Herwig
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 296 : 202 - 207
  • [3] Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
    Hattasingh, Weerawan
    Chanthavanich, Pornthep
    Sirivichayakul, Chukiat
    Arunsodsai, Watcharee
    Surangsrirat, Surachai
    Srisuwannaporn, Termsang
    Kaewma, Benjawan
    Yoksan, Sutee
    Limkittikul, Kriengsak
    Yang, Junwei
    Mao, Yu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [4] Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur® Children
    Wittermann, Christoph
    Petri, Eckhardt
    Zent, Olaf
    VACCINE, 2009, 27 (10) : 1585 - 1588
  • [5] Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination
    Paulke-Korinek, Maria
    Kundi, Michael
    Laaber, Brigitte
    Brodtraeger, Natascha
    Seidl-Friedrich, Claudia
    Wiedermann, Ursula
    Kollaritsch, Herwig
    VACCINE, 2013, 31 (09) : 1293 - 1297
  • [6] IXIARO® updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis
    Jelinek, Tomas
    EXPERT REVIEW OF VACCINES, 2013, 12 (08) : 859 - 869
  • [7] A new inactivated Japanese encephalitis vaccine for adult travelers
    Toovey, Stephen
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2009, 7 (05) : 301 - 304
  • [8] Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children
    Janewongwirot, Pakpoom
    Puthanakit, Thanyawee
    Anugulruengkitt, Suvaporn
    Jantarabenjakul, Watsamon
    Phasomsap, Chayapa
    Chumket, Sompong
    Yoksan, Sutee
    Pancharoen, Chitsanu
    VACCINE, 2016, 34 (44) : 5279 - 5283
  • [9] Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine
    Vadrevu, Krishna Mohan
    Potula, Venugopal
    Khalatkar, Vasant
    Mahantshetty, Niranjana S.
    Shah, Atish
    Ella, Raches
    JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (09) : 1478 - 1487
  • [10] Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules
    Costantini, Marco
    Callegaro, Andrea
    Beran, Jiri
    Berlaimont, Valerie
    Galgani, Ilaria
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (09) : 2274 - 2279